TY - JOUR
T1 - Ongoing and Future Clinical Trials of Pharmacotherapy for Heart Failure
AU - Mansoor, Taha
AU - Khalid, Subaina N.
AU - Bilal, Muhammad Ibraiz
AU - Ijaz, Sardar Hassan
AU - Fudim, Marat
AU - Greene, Stephen J.
AU - Warraich, Haider J.
AU - Nambi, Vijay
AU - Virani, Salim S.
AU - Fonarow, Gregg C.
AU - Abramov, Dmitry
AU - Minhas, Abdul Mannan Khan
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024.
PY - 2024/7
Y1 - 2024/7
N2 - Increasing knowledge of the processes leading to heart failure (HF) has allowed significant developments in therapies for HF over the past few decades. Despite the evolution of HF treatment, it still places a large burden on patients and health care systems across the world. We used clinicaltrials.gov to gather information about clinical trials as of August 2023 studying pharmacotherapy for HF. We included interventional trials that were “active, not recruiting”, “recruiting”, or looking for participants but “not yet recruiting”. In total, 119 studies met our criteria of ongoing clinical trials studying novel as well as currently approved HF pharmacotherapies. The major interventions were novel medications/already approved medications for other diseases 29 % (34 trials), sodium-glucose co-transporter inhibitors 21 % (25 trials), angiotensin receptor blocker-neprilysin inhibitors 10 % (12 trials), diuretics 14 % (17 trials) and mineralocorticoid receptor antagonists 5 % (6 trials). Ongoing research will aid in reducing the impact of HF and we summarize clinical trials leading the way to better HF treatment in this review.
AB - Increasing knowledge of the processes leading to heart failure (HF) has allowed significant developments in therapies for HF over the past few decades. Despite the evolution of HF treatment, it still places a large burden on patients and health care systems across the world. We used clinicaltrials.gov to gather information about clinical trials as of August 2023 studying pharmacotherapy for HF. We included interventional trials that were “active, not recruiting”, “recruiting”, or looking for participants but “not yet recruiting”. In total, 119 studies met our criteria of ongoing clinical trials studying novel as well as currently approved HF pharmacotherapies. The major interventions were novel medications/already approved medications for other diseases 29 % (34 trials), sodium-glucose co-transporter inhibitors 21 % (25 trials), angiotensin receptor blocker-neprilysin inhibitors 10 % (12 trials), diuretics 14 % (17 trials) and mineralocorticoid receptor antagonists 5 % (6 trials). Ongoing research will aid in reducing the impact of HF and we summarize clinical trials leading the way to better HF treatment in this review.
UR - http://www.scopus.com/inward/record.url?scp=85196616596&partnerID=8YFLogxK
U2 - 10.1007/s40256-024-00658-0
DO - 10.1007/s40256-024-00658-0
M3 - Review article
AN - SCOPUS:85196616596
SN - 1175-3277
VL - 24
SP - 481
EP - 504
JO - American Journal of Cardiovascular Drugs
JF - American Journal of Cardiovascular Drugs
IS - 4
ER -